Abstract: Disclosed are methods of eliminating at least one target cell in a subject, comprising administering to the subject an effective amount of a composition comprising a plurality of immune cells, wherein each immune cell of the plurality expresses one or more chimeric ligand receptor(s) (CLR(s)) that each specifically bind to a target ligand on the at least one target cell, wherein specifically binding of the one or more CLR(s) to the target activates the immune cell, and wherein the activated immune cell induces death of the target cell. Exemplary target cells include, but are not limited to, hematopoietic stem cells (HSCs).

Abstract: The present disclosure is directed to compositions and methods for the treatment of hemophilia. The compositions and methods can comprise an adeno-associated virus (AAV) piggyBac polynucleotide comprising a transgene. The transgene may comprise ornithine Factor VIII (FVIII) or Factor IX (FIX).

Abstract: Disclosed are methods of eliminating at least one target cell in a subject, comprising administering to the subject an effective amount of a composition comprising a plurality of immune cells, wherein each immune cell of the plurality expresses one or more chimeric ligand receptor(s) (CLR(s)) that each specifically bind to a target ligand on the at least one target cell, wherein specifically binding of the one or more CLR(s) to the target activates the immune cell, and wherein the activated immune cell induces death of the target cell. Exemplary target cells include, but are not limited to, hematopoietic stem cells (HSCs).

Abstract: Disclosed are methods of eliminating at least on target cell in a subject, comprising administering to the subject an effective amount of a composition comprising a plurality of immune cells, wherein each immune cell of the plurality expresses one or more chimeric ligand receptor(s) (CLR(s)) that each specifically bind to a target ligand on the at least one target cell, wherein specifically binding of the one or more CLR(s) to the target activates the immune cell, and wherein the activated immune cell induces death of the target cell. Exemplary target cells include, but are not limited to, hematopoietic stem cells (HSCs).

Abstract: The invention relates to compounds of formula (I) which are inhibitors of kinase activity, pharmaceutical formulations containing the compounds and their uses in treating and preventing viral infections and disorders caused or exacerbated by the viral infection wherein R1, R2, R3, R4a, R4b, R4c, R5, W, X, Y and Z are defined herein.

Abstract: The invention is directed to compounds of formula (I), and salts thereof. The compounds are inhibitors of kinase activity, in particular PI3-kinase activity.

Abstract: The invention is directed to compounds of formula (I), and salts thereof. The compounds are inhibitors of kinase activity, in particular PI3-kinase activity.

Abstract: The invention relates to compounds of formula (I) which are inhibitors of kinase activity, pharmaceutical formulations containing the compounds and their uses in treating and preventing viral infections and disorders caused or exacerbated by the viral infection wherein R1, R2, R3, R4a, R4b, R4c, R5, W, X, Y and Z are defined herein.

Abstract: A container including a finish defining an opening at a first end of the container that provides access to an internal volume defined by the container. A base portion of the container includes a diaphragm that is concave relative to an exterior of the container. The diaphragm extends from a standing surface of the container to a center push-up portion of the base portion. The standing surface is at a second end of the container opposite to the first end. The diaphragm is configured to move from an as-blown first configuration to a second configuration in which the diaphragm is closer to the first end as compared to the first configuration in order to reduce residual vacuum within the container. The diaphragm is generally hemispherical in cross-section when in the second configuration.

Abstract: A system for deploying a first object for capturing, immobilising or disabling a second object is provided. The system comprises the first object, a projectile for carrying the first object therein, and a launcher for launching the projectile towards the second object, wherein the projectile is configured for deploying the first object in the vicinity of the second object for capturing, immobilising or disabling the second object.

Abstract: The invention is directed to certain novel compounds. Specifically, the invention is directed to compounds of formula (I): and salts thereof. The compounds of the invention are inhibitors of kinase activity, in particular PI3-kinase activity.

Abstract: Disclosed are methods of eliminating at least on target cell in a subject, comprising administering to the subject an effective amount of a composition comprising a plurality of immune cells, wherein each immune cell of the plurality expresses one or more chimeric ligand receptor(s) (CLR(s)) that each specifically bind to a target ligand on the at least one target cell, wherein specifically binding of the one or more CLR(s) to the target activates the immune cell, and wherein the activated immune cell induces death of the target cell. Exemplary target cells include, but are not limited to, hematopoietic stem cells (HSCs).

Abstract: The invention is directed to certain novel compounds. Specifically, the invention is directed to compounds of formula (I): and salts thereof. The compounds of the invention are inhibitors of kinase activity, in particular PI3-kinase activity.

Abstract: A system for inhibiting the electronic system of a target object is provided. The system comprises an Electronic Counter Measure (ECM) unit, and a projectile for carrying the ECM unit towards the target object.

Abstract: A container including a finish defining an opening at a first end of the container that provides access to an internal volume defined by the container. A base portion of the container includes a diaphragm that is concave relative to an exterior of the container. The diaphragm extends from a standing surface of the container to a center push-up portion of the base portion. The standing surface is at a second end of the container opposite to the first end. The diagram is configured to move from an as-blown first configuration to a second configuration in which the diaphragm is closer to the first end as compared to the first configuration in order to reduce residual vacuum within the container. The diaphragm is generally hemispherical in cross-section when in the second configuration.

Abstract: The invention is directed to certain novel compounds. Specifically, the invention is directed to compounds of formula (I): and salts thereof. The compounds of the invention are inhibitors of kinase activity, in particular PI3-kinase activity.

Abstract: A method for acquiring a remote object is provided. The method comprises obtaining a sequence of position samples of the remote object, identifying one or more sets of spatially clustered position samples from among the obtained position samples, and applying curve-fitting to at least one set of spatially clustered position samples to obtain a trajectory of the set of spatially clustered position samples. Also provided is a method for tracking a remote object. The method comprising obtaining an estimated trajectory of the object, obtaining one or more position samples of the object, comparing the obtained position samples with positions computed based on the estimated trajectory, and determining that the object is being tracked based on whether the obtained position samples are consistent with the computed positions.

Abstract: A child resistant closure for use on a container that include an inner closure member having a threaded portion and an outer closure member coupled to the inner closure member for axial translation there between. A series of engagement features extend between the inner and outer closure to permit selective engagement of the outer closure to the inner closure to effect removal of the child resistant closure. The outer closure includes a diaphragm member disposed along the distal end surface of the outer closure. The diaphragm member is inwardly directed and contacts the inner closure member thereby biasing the outer closure member into an operationally disengaged position.

Abstract: The invention is directed to certain novel compounds. Specifically, the invention is directed to compounds of formula (I): and salts thereof. The compounds of the invention are inhibitors of kinase activity, in particular PI3-kinase activity.

Abstract: A system for inhibiting the electronic system of a target object is provided. The system comprises an Electronic Counter Measure (ECM) unit, and a projectile for carrying the ECM unit towards the target object.